Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
Joly F, Bazan F, Garbay Decoopman D, Ouldbey Y, Follana P, Champeaux-Orange É, Legouffe E, Brachet PE, Spaeth D, Combe P, Hardy-Bessard AC, Selle F, Grenier J, Lebreton C, Derbel O, Bonnet E, Fournel P, Fernandez Diez Y, Delecroix V, Emambux S, Alexandre J, Grellety T, Mille D, Orfeuvre H, Favier C, Le Roux D, Mouret-Reynier MA, Quesada S, Kurtz JE.
Joly F, et al. Among authors: quesada s.
JNCI Cancer Spectr. 2024 Dec 14:pkae114. doi: 10.1093/jncics/pkae114. Online ahead of print.
JNCI Cancer Spectr. 2024.
PMID: 39673810